there is limited use of medications to treat addictions: Lack of financial resources to pay for addiction medications at the state, program, or patient levels, [15] [16] [17] lack of medical staff with prescribing privileges, 17 physicians' reluctance to prescribe medications for addictions, 14, 18, 19 and regulatory dispensing barriers. 5, 17 For some treatment programs and clinicians, the barrier may be the philosophical belief that medications
should not be used to treat addictions despite the overwhelming evidence of efficacy and effectiveness. 20 It takes approximately 17 years for a clinical discovery to be integrated into routine medical practice, 21 hence there have been major efforts throughout medicine to increase the rate of adoption of EBPs. The NIDA formed the CTN in 1999 to improve the quality of substance use disorder (SUD) treatment and to enhance adoption of EBPs for SUDs by establishing a unique collaboration between regional research and training centers (RRTCs), which are university based, and CTPs. 21 The NIDA CTN created the infrastructure for bidirectional collaboration between researchers and clinicians on research projects to ensure that the design, methods, and findings would be highly relevant to community providers.
To date, the NIDA CTN has conducted over 50 clinical trials and has enrolled more than 16,000 study participants. Currently, the NIDA CTN has 13 nodes representing
RRTCs that facilitate and coordinate research projects with 183 CTPs where the research projects may be conducted. 
Key Points

Adoption of Medications at Maryhaven
Maryhaven is central Ohio's oldest and largest addiction treatment facility with admissions of more than 7,000 annually. Before joining the NIDA CTN, there were no specific empirically supported addiction treatment practices being used at Maryhaven. Maryhaven primarily used a Twelve-
Step-based approach to psychosocial treatment. 23 dardized clinical assessments that measured opioid withdrawal, which is important to ensure that the dose relieves withdrawal symptoms without causing oversedation. Maryhaven used this training and first-hand clinical experience using buprenorphine to tailor the CTN-0001 taper schedule for their patient population. 23 Upon implementation of buprenorphine as medication for detoxification, the leadership at Maryhaven was able to realize that they had the organizational capacity to implement medication assisted treatments and that medications could improve outcomes for their patients. However, Maryhaven's use of buprenorphine as a detoxification medication was not sufficient to quell ambivalence among staff regarding the use of medications to prevent relapse and one counselor said, "I know it works but I worry that it is too easy." Still, the success with buprenorphine as a medication for detoxification was sufficient to motivate the administration and staff to continue a dialogue on the utility of longer durations of maintenance medications to prevent relapse.
A major milestone was when Maryhaven adopted methadone and opened an outpatient opiate treatment program.
This happened through a lengthy contentious process that was Midtown's experience using this new medication during the CTN study was very successful and buprenorphine was perceived as a positive treatment option. Treatment programs with no experience using psychiatric or addiction medications are less likely to adopt new medications for SUDs. 13 Although
Midtown had adopted methadone before joining the NIDA CTN, the adoption of buprenorphine was complicated and took longer than anyone anticipated, in part because Midtown is part of a large medical system that includes a public hospital. However, the delay in buprenorphine adoption at Midtown was 
Challenges at Midtown
ConClusions
Research suggests that participation in the NIDA CTN facilitates adoption of EBPs for SUDs. 24 Research has found that SUD treatment programs within the NIDA CTN are two to three times more likely to adopt buprenorphine. 25, 26 CTPs that participated in the NIDA CTN buprenorphine clinical trials are even more likely to have adopted buprenorphine. 14, 25 Maryhaven and Midtown are two CTPs that were motivated to adopt medications for the treatment of opioid dependence by their involvement in a CTN and were able to sustain efforts to overcome many of the known barriers to medication adoption.
Based on Rogers's theory on the diffusion of innovations, five factors that facilitate adoption of innovations are relative advantage, trialability, observability, compatibility, and simplicity. 27 Leadership and staff at both CTPs believed that outcomes for opioid treatment could be improved (perceived need for benefit) and participated in clinical studies, which provided the opportunity for trialability and observability.
Both CTPs were able to gain the clinical skills necessary for adoption and to obtain data that demonstrated improvement in patient outcomes at their respective treatment programs by participating in the NIDA CTN (observability). Compatibility of opioid medications can present a barrier at the philosophical and structural levels. Lack of buy-in from clinic staff and leadership is frequently reported as a significant barrier to medication adoption. 14, 19, 20 An abstinence-based recovery approach to addiction treatment was a major barrier at
Maryhaven that was, ultimately, addressed by an incremental process of adoption that resulted in a medication-assisted recovery philosophy. However, philosophical barriers to medication use were not a barrier at Midtown may be owing to Midtown being part of a larger medical system where medications are used on a routine basis to treat psychiatric and medical conditions. Adoption of medications within the addiction specialty treatment system is not simplistic, given that outpatient treatment programs infrequently have the medical staff needed to prescribe medications. 17 The ability to adopt evidence-based medications to treat addiction requires knowledge of induction, dosing, and tapering; clinicians that can and will prescribe; methods to pay for medications; and technical assistance for clinically complicated patients. Table 1 
